Bristol-Myers Squibb.

These trials randomized 12 nearly,000 patients and assessed the security and efficacy of Eliquis compared to enoxaparin. ADVANCE-2 and ADVANCE-1 studied sufferers undergoing elective total knee substitution, and ADVANCE-3 studied individuals undergoing elective hip alternative.. Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review Bristol-Myers Squibb Business and Pfizer Inc. today announced that the U.S. The Prescription Drug User Fee Act goal day for a decision by the FDA is definitely March 15, 2014. Related StoriesMayo Clinic hospitals gain top-tier Large Performing distinction in U.S. News & World Survey ratingsColorado PERA now offers brand-new hip and knee substitute benefit option for retirees in pre-Medicare programLower socioeconomic status significantly increases threat of pain following knee replacement The ADVANCE-1 supports The submission, ADVANCE-2, and ADVANCE-3 medical trials, area of the EXPANSE medical trial program.Kaiser Health Information, an editorially independent news service, is a program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.. Bipolar subtypes display neurobiologic differences By Tag Cowen, Senior medwireNews Reporter Outcomes from a Taiwanese research show there are significant neurobiologic differences between sufferers with bipolar We and II disorder. The group discovered that remitted BD I sufferers had changed patterns of glucose uptake in a number of brain regions weighed against BD II individuals.